PL376147A1 - Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof - Google Patents

Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Info

Publication number
PL376147A1
PL376147A1 PL03376147A PL37614703A PL376147A1 PL 376147 A1 PL376147 A1 PL 376147A1 PL 03376147 A PL03376147 A PL 03376147A PL 37614703 A PL37614703 A PL 37614703A PL 376147 A1 PL376147 A1 PL 376147A1
Authority
PL
Poland
Prior art keywords
cystic fibrosis
protein inhibitors
fibrosis transmembrane
conductance regulator
transmembrane conductance
Prior art date
Application number
PL03376147A
Other languages
Polish (pl)
Inventor
Alan Verkman
Tonghui Ma
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/262,573 external-priority patent/US20040063695A1/en
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of PL376147A1 publication Critical patent/PL376147A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
PL03376147A 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof PL376147A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/262,573 US20040063695A1 (en) 2002-09-30 2002-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US48025303P 2003-06-20 2003-06-20

Publications (1)

Publication Number Publication Date
PL376147A1 true PL376147A1 (en) 2005-12-27

Family

ID=32044981

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03376147A PL376147A1 (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Country Status (13)

Country Link
EP (1) EP1549321A4 (en)
JP (1) JP4977319B2 (en)
KR (1) KR20050061501A (en)
CN (1) CN100356922C (en)
AP (1) AP2005003292A0 (en)
AU (1) AU2003277162C1 (en)
BR (1) BR0314943A (en)
CA (1) CA2500498C (en)
EA (1) EA009847B1 (en)
MX (1) MXPA05003366A (en)
NZ (1) NZ538809A (en)
PL (1) PL376147A1 (en)
WO (1) WO2004028480A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3091011T3 (en) 2006-04-07 2018-02-26 Vertex Pharma MODULATORS OF ATP BINDING CASSETTE TRANSPORT
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8283351B2 (en) 2007-04-02 2012-10-09 Institute For Oneworld Health Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof
WO2009038913A2 (en) * 2007-08-24 2009-03-26 Vertex Pharmaceuticals Incorporated Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
ES2445447T3 (en) 2007-11-16 2014-03-03 Vertex Pharmaceuticals Inc. Isoquinoline modulators of ATP binding cassette transporters
KR20100101130A (en) 2007-12-07 2010-09-16 버텍스 파마슈티칼스 인코포레이티드 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
KR20100134063A (en) * 2008-03-25 2010-12-22 더 리전트 오브 더 유니버시티 오브 캘리포니아 Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
NZ616097A (en) 2008-03-31 2015-04-24 Vertex Pharma Pyridyl derivatives as cftr modulators
WO2009131951A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2010033626A1 (en) * 2008-09-19 2010-03-25 Institute For Oneworld Health Compounds, compositions and methods comprising imidazole and triazole derivatives
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US20120219543A1 (en) * 2009-10-20 2012-08-30 Raphael Scharfmann Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
PL3835297T3 (en) 2010-03-25 2023-09-11 Vertex Pharmaceuticals Incorporated Synthesis and intermediates of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide
LT3150198T (en) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
RU2579370C2 (en) 2010-04-07 2016-04-10 Вертекс Фармасьютикалз Инкорпорейтед Solid forms of 3-(2, 2-difluorobenzo[d][1,3] dioxol-5-yl)cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoic acid
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CN103153287A (en) 2010-08-23 2013-06-12 弗特克斯药品有限公司 Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
CN102133402B (en) * 2011-03-24 2013-06-12 首都医科大学附属北京同仁医院 Application of cystic fibrosis transmembrane transduction regulating factor inhibitor to preparation of medicaments for treating diabetes
JP6014816B2 (en) 2011-05-10 2016-10-26 国立大学法人神戸大学 Thioxothiazolidine derivative having Ras function inhibitory action
WO2013070961A1 (en) 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
RU2644723C2 (en) 2012-01-25 2018-02-13 Вертекс Фармасьютикалз Инкорпорейтед Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzonic acid
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
IL283276B1 (en) 2012-11-02 2024-01-01 Vertex Pharma Compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and n-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide and uses thereof
FR2999191B1 (en) 2012-12-12 2016-02-05 Lesaffre & Cie PROBIOTIC STRAINS FOR THE TREATMENT AND / OR PREVENTION OF DIARRHEA
PL3925607T3 (en) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
CN112250627B (en) 2014-10-06 2024-02-02 弗特克斯药品有限公司 Cystic fibrosis transmembrane conductance regulator modulators
CN104398509B (en) * 2014-11-13 2017-01-11 四川大学华西第二医院 Application of CFTR (cystic fibrosis transmembrane conductance regulator) inhibitor CFTRinh-172 in preparation of drug for prevention and treatment of leukemia cell mediated diseases
CN104788423B (en) * 2015-03-13 2016-10-26 成都理工大学 A kind of new cystic fibrosis transmembrane conductance regulator inhibitor
EP3394083B9 (en) 2015-12-24 2022-04-27 The Regents of the University of California N-[5-[(3,4-dimethoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]-2-methoxy-benzeneacetamide derivatives and related compounds as cftr activators for treating constipation or cholestasis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96654A (en) * 1989-12-21 1995-06-29 Lilly Co Eli Hydroxybenzyl substituted sulfur containing heterocyclic derivatives their preparation and pharmaceutical compositions containing them
AU1090795A (en) * 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
UA56185C2 (en) * 1996-09-30 2003-05-15 Пфайзер Інк. Aralkyl- and aralkylidene heterocyclic lactams and imids, a pharmaceutical composition and a treatment method
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
CN1325309A (en) * 1998-08-21 2001-12-05 维洛药品公司 Compounds, compositions and method for treating or preventing viral infections and associated diseases
US6484397B1 (en) * 2000-07-11 2002-11-26 Corning Incorporated Method of assembling a catalytic converter for use in an internal combustion engine
US20020052396A1 (en) * 2001-04-23 2002-05-02 Bailey Thomas R. Compounds, compositions and methods for treating or preventing viral infections and associated diseases

Also Published As

Publication number Publication date
AP2005003292A0 (en) 2005-06-30
KR20050061501A (en) 2005-06-22
EP1549321A4 (en) 2007-05-23
WO2004028480A2 (en) 2004-04-08
AU2003277162C1 (en) 2009-12-24
WO2004028480A3 (en) 2004-07-01
CA2500498C (en) 2012-08-21
BR0314943A (en) 2005-08-02
NZ538809A (en) 2008-06-30
MXPA05003366A (en) 2005-10-05
EP1549321A2 (en) 2005-07-06
AU2003277162B2 (en) 2009-07-16
AU2003277162A1 (en) 2004-04-19
CA2500498A1 (en) 2004-04-08
CN100356922C (en) 2007-12-26
EA009847B1 (en) 2008-04-28
JP2006503853A (en) 2006-02-02
CN1684686A (en) 2005-10-19
EA200500583A1 (en) 2005-12-29
JP4977319B2 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
AP2005003292A0 (en) Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
EP1495128A4 (en) Ehanced protein expression in bacillus
PL375447A1 (en) Protein kinase inhibitors and uses thereof
AU2003270341A1 (en) Modified asialo-interferons and uses thereof
HUP0301063A3 (en) Benzoic-acid isononylesters and applying them
AU2003222225A1 (en) Receptors and membrane-associated proteins
AU2003280084A1 (en) Protein arrays and uses thereof
AUPS238502A0 (en) Cystic echinococcosis protein and uses therefor
AU2003268023A8 (en) Protein modification and maintenance molecules
AU2002348834A8 (en) Method and system providing user mobility in a mobile-ip-network by means of a personal ip address
AU2003239871A8 (en) Protein modification and maintenance molecules
AU2003301112A1 (en) Hand and fingernail cleaning apparatus
AU2003231981A8 (en) Protein modification and maintenance molecules
EP1541677A4 (en) Novel proteins and use thereof
AU2003291426A8 (en) Gp64-pseudotyped vectors and uses thereof
AU2003292774A1 (en) Novel proteins and use thereof
AU7080601A (en) Activation of the cystic fibrosis transmembrane conductance regulator chloride channel
AU2003260487A8 (en) Novel pancortin-pablo protein interactions and methods of use thereof
AU2003202650A1 (en) Cystic echinococcosis protein and uses therefor
AU2003249644A8 (en) Mutant p53 (delta126-132) protein and uses thereof
EP1549951A4 (en) Semaphorin-like proteins and methods of using same
AU2003270876A8 (en) Anti-hla assay and methods
AU2003295437A1 (en) Receptors and membrane-associated proteins
AU2003265814A8 (en) Aw755252-interacting proteins and use thereof
AU2003263751A8 (en) Novel proteins and their uses

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)